Trillium Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Trillium Therapeutics Inc.
Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago
Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.
Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Merck Extends Timeline On Acceleron Deal, Still Expects Q4 Close
Merck said it is giving the FTC more time to review the acquisition, but the shift also gives the company leeway to convince any reluctant Acceleron shareholders to trade their shares for cash.
- Large Molecule
- Other Names / Subsidiaries
- Fluorinov Pharma Inc., Neurogenesis Biotech Corp.
- Stem Cell Therapeutics Corp.
- Trillium Therapeutics USA Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.